Clinical trial
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy…
NCT00006083 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006083 |
|---|---|
| Title | Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter |
| Official title | A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Upjohn Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease |
| Intervention type | Drug, Other |
| Interventions | Fragmin, placebo |
| Start date | Apr 1, 2000 |
| Primary completion | Nov 1, 2000 |
| Completion | Nov 1, 2000 |
| First posted | May 26, 2004 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: